Q-omics provides the consensus-scored MIR4639 profile across patient tissues and cancer cell-line models. MIR4639 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, MIR4639 is differentially expressed in 4, with the highest sampling consensus in PRAD. Additionally, MIR4639 RNA expression shows 15,495 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUSC, PRAD, and UVM as cancer lineages where MIR4639 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4639 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4639 survival associations across molecular data types. MIR4639 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4639 RNA expression–survival associations across cancer types. High MIR4639 expression shows unfavorable associations in READ, but favorable associations in LUSC, OV, LUAD, CHOL and SKCM. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for MIR4639 RNA expression.
This table summarizes MIR4639 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4639. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4639 shows higher tumor expression in PRAD, KIRC, CHOL and STAD. The PRAD box plot shows higher MIR4639 RNA expression in tumor versus normal tissue (log2 FC = +0.342, t-test p = .011).
This table shows molecular features associated with MIR4639 in patient tissues and cancer cell lines. In patient samples, MIR4639 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
